Gilead Buys Kite Pharma for Nearly $12 Billion
Gilead's acquisition of Kite Pharma is expected to close in 2017 Q4 and will diversify Gilead's pipeline with the addition of Kite's cell-based cancer therapies.
Read the story in The New York Times.
HPV Vaccination Rates Up in US
The CDC reports that 60% of US teens have received at least one dose of the HPV vaccine, although many do not get the recommended second dose. The vaccination rates are on the rise, but there is still work to be done. Our post has more details on using anti HPV T cells and HPV peptides to find new treatments.
Read the full press release.
Oxeia's Concussion Drug Gets NFL Partnership with Richard Sherman
Richard Sherman of the Seattle Seahawks has joined the board of Oxeia Biopharmaceuticals to raise awareness of brain health, concussions, and Oxeia's early stage concussion drug.
Read the story on FiercePharma.
Find out what's happening in Seattlefor free with the latest updates from Patch.
This post originally appeared on the Astarte Biologics blog and has been modified for Patch.
